Atomoxetine in the Treatment of Binge Eating Disorder

L

Lindner Center of HOPE

Status and phase

Completed
Phase 4

Conditions

Binge-eating Disorder

Treatments

Drug: atomoxetine

Study type

Interventional

Funder types

Other

Identifiers

NCT00327834
B4Z-US-X009

Details and patient eligibility

About

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
  • In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion criteria

  • Have concurrent symptoms of bulimia nervosa or anorexia nervosa
  • Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
  • Patients who are displaying clinically significant suicidality or homicidality

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems